The NSCLC treatment landscape has evolved with the clinical development and approval of molecular-targeted therapies for patients with specific molecular features, notably epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI), accompanied by EGFR mutation testing (3). Here, EGFR is linked to non-small cell lung carcinoma.